Ibrutynib przed i po przeszczepie komórek macierzystych w leczeniu pacjentów z nawracającym lub opornym na leczenie chłoniakiem rozlanym z dużych komórek B
Randomizowane, podwójnie ślepe badanie fazy III dotyczące stosowania ibrutynibu w trakcie i po autologicznym przeszczepieniu komórek macierzystych w porównaniu z placebo u pacjentów z nawracającym lub opornym na leczenie chłoniakiem rozlanym z dużych komórek B aktywowanego podtypu komórek B
This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Before transplant, stem cells are taken from patients and stored. Patients then receive high doses of chemotherapy to kill cancer cells and make room for healthy cells. After treatment, the stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Ibrutinib is a drug that may stop the growth of cancer cells by blocking a protein that is needed for cell growth. It is not yet known whether adding ibrutinib to chemotherapy before and after stem cell transplant may help the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
- Inny: Laboratory Biomarker Analysis
- Lek: Cyclophosphamide
- Lek: Cytarabine
- Inny: Placebo Administration
- Lek: Ibrutinib
- Lek: Etoposide
- Lek: Melphalan
- Inny: Pharmacogenomic Study
- Procedura: Autologous Bone Marrow Transplantation
- Procedura: Autologous Hematopoietic Stem Cell Transplantation
- Lek: Carmustine
Szczegółowy opis
PRIMARY OBJECTIVE:
I. To evaluate the ability of ibrutinib to improve 24-month progression free survival (PFS) compared to placebo in patients with non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) as determined by immunohistochemistry (IHC).
SECONDARY OBJECTIVES:
I. To evaluate the ability of ibrutinib to improve overall survival (OS) compared to placebo.
II. To evaluate the ability of ibrutinib to improve progression free survival (PFS) compared to placebo.
III. To evaluate the ability of ibrutinib to improve post-transplant response rates compared to placebo.
IV. To evaluate time to hematopoietic recovery in the two arms. V. To evaluate the safety and tolerability of ibrutinib compared to placebo. VI. To evaluate the incidence of secondary malignancies in the two arms. VII. To evaluate immune reconstitution in the two arms.
CORRELATIVE SCIENCE OBJECTIVES:
I. To assess whether pre-autologous hematopoietic stem cell transplantation (AutoHCT) positive fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) is associated with inferior 24-month PFS as well as PFS and OS.
II. To assess whether pre-AutoHCT FDG-PET results are differentially associated with 24-month PFS, PFS and OS in the ibrutinib versus placebo arms.
III. To evaluate the application of the Lugano criteria and change in quantitative measurements between pre-AutoHCT and post AutoHCT (e.g. delta standard uptake variable [SUV], %SUV decline and %metabolic tumor volume [MTV] decline, and other available applicable quantitative measurements) to assess the association between changes in these variables and outcomes, such as PFS and OS.
IV. To assess whether the GSTT1 null polymorphism is correlated with pulmonary toxicity after BCNU (carmustine)-containing conditioning regimens as part of autologous stem cell transplantation.
V. To assess whether other polymorphisms in the BCNU metabolism pathway or BCNU damage repair pathway(s) are associated with pulmonary toxicity after BCNU-containing conditioning regimens as part of autologous stem cell transplantation.
VI. To evaluate whether any of the proposed deoxyribonucleic acid (DNA) polymorphisms are associated with other toxicities.
VII. To assess whether DLBCL subtype based on the lymphoma subtyping test (LST) is associated with 24-month PFS, PFS, and OS with ibrutinib compared to placebo in patients treated on this protocol.
VIII. To assess whether activating mutations in the BCR pathway are associated with response to ibrutinib and with clinical outcomes in patients treated on this protocol.
IX. To assess whether there are any phenotypic associations with IHC markers (particularly MYC protein expression level) and presence of these mutations.
X. To assess whether BCL2, MYC, and Ki67 expression by IHC affect clinical outcomes in patients treated on this protocol.
XI. To assess whether translocations in MYC with or without BCL2 and BC6 have poor outcomes in patients treated on this protocol and whether ibrutinib modifies the prognosis.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
CONDITIONING REGIMEN:
ARM I: Investigators may choose to use either the BEAMi (carmustine, etoposide, cytarabine, melphalan, ibrutinib) or CBVi (cyclophosphamide, carmustine, etoposide, ibrutinib) regimen.
BEAMi: Patients receive ibrutinib orally (PO) on days -6 to -1, carmustine intravenously (IV) over 2 hours on day -6, etoposide IV twice daily (BID) over 1-2 hours and cytarabine IV BID over 1-2 hours on days -5 to -2, and melphalan IV over 20-30 minutes on day -1. Optionally, if a day of rest is planned, patients may receive BEAMi on days -7 to -2.
CBVi: Patients receive ibrutinib PO on days -6 to -1, carmustine IV over 2 hours on day -6, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. Optionally, if a day of rest is planned, patients may receive CBVi on days -7 to -2.
ARM II: Patients receive placebo PO on days -6 to -1 and receive 1 of the 2 conditioning regimens as in Arm I.
TRANSPLANT: In both arms, patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0.
CONTINUATION REGIMEN:
ARM I: Beginning 30-60 days after transplant, patients receive ibrutinib PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Beginning 30-60 days after transplant, patients receive placebo PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover Arm I.
After completion of treatment, patients are followed up every 6 months for up to 60 months from registration.
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Riyadh, Arabia Saudyjska, 11211
- King Faisal Specialist Hospital and Research Centre
-
-
-
-
Alaska
-
Anchorage, Alaska, Stany Zjednoczone, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Stany Zjednoczone, 99504
- Anchorage Radiation Therapy Center
-
Fairbanks, Alaska, Stany Zjednoczone, 99701
- Fairbanks Memorial Hospital
-
-
Arizona
-
Tucson, Arizona, Stany Zjednoczone, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Stany Zjednoczone, 85719
- University of Arizona Cancer Center-North Campus
-
-
California
-
Burbank, California, Stany Zjednoczone, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Duarte, California, Stany Zjednoczone, 91010
- City of Hope Comprehensive Cancer Center
-
La Jolla, California, Stany Zjednoczone, 92093
- UC San Diego Moores Cancer Center
-
Loma Linda, California, Stany Zjednoczone, 92354
- Loma Linda University Medical Center
-
Los Angeles, California, Stany Zjednoczone, 90048
- Cedars-Sinai Medical Center
-
Orange, California, Stany Zjednoczone, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Sacramento, California, Stany Zjednoczone, 95817
- University of California Davis Comprehensive Cancer Center
-
San Francisco, California, Stany Zjednoczone, 94143
- UCSF Medical Center-Parnassus
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Stany Zjednoczone, 80012
- The Medical Center of Aurora
-
Aurora, Colorado, Stany Zjednoczone, 80045
- UCHealth University of Colorado Hospital
-
Boulder, Colorado, Stany Zjednoczone, 80303
- Boulder Community Foothills Hospital
-
Boulder, Colorado, Stany Zjednoczone, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs, Colorado, Stany Zjednoczone, 80909
- UCHealth Memorial Hospital Central
-
Denver, Colorado, Stany Zjednoczone, 80218
- Presbyterian - Saint Lukes Medical Center - Health One
-
Denver, Colorado, Stany Zjednoczone, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Stany Zjednoczone, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, Stany Zjednoczone, 80204
- Denver Health Medical Center
-
Denver, Colorado, Stany Zjednoczone, 80218
- Colorado Blood Cancer Institute
-
Denver, Colorado, Stany Zjednoczone, 80209
- The Women's Imaging Center
-
Denver, Colorado, Stany Zjednoczone, 80206
- National Jewish Health-Main Campus
-
Denver, Colorado, Stany Zjednoczone, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Englewood, Colorado, Stany Zjednoczone, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Stany Zjednoczone, 80113
- Swedish Medical Center
-
Fort Collins, Colorado, Stany Zjednoczone, 80524
- Poudre Valley Hospital
-
Golden, Colorado, Stany Zjednoczone, 80401
- National Jewish Health-Western Hematology Oncology
-
Grand Junction, Colorado, Stany Zjednoczone, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Grand Junction, Colorado, Stany Zjednoczone, 81505
- Grand Valley Oncology
-
Greeley, Colorado, Stany Zjednoczone, 80631
- Banner North Colorado Medical Center
-
Lafayette, Colorado, Stany Zjednoczone, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
Littleton, Colorado, Stany Zjednoczone, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, Stany Zjednoczone, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland, Colorado, Stany Zjednoczone, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Wheat Ridge, Colorado, Stany Zjednoczone, 80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
New Haven, Connecticut, Stany Zjednoczone, 06520
- Yale University
-
New Haven, Connecticut, Stany Zjednoczone, 06510
- Smilow Cancer Center/Yale-New Haven Hospital
-
-
Delaware
-
Lewes, Delaware, Stany Zjednoczone, 19958
- Beebe Medical Center
-
Newark, Delaware, Stany Zjednoczone, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Stany Zjednoczone, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Stany Zjednoczone, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Stany Zjednoczone, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Stany Zjednoczone, 19971
- Beebe Health Campus
-
Seaford, Delaware, Stany Zjednoczone, 19973
- TidalHealth Nanticoke / Allen Cancer Center
-
Wilmington, Delaware, Stany Zjednoczone, 19801
- Christiana Care Health System-Wilmington Hospital
-
-
Florida
-
Deerfield Beach, Florida, Stany Zjednoczone, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Gainesville, Florida, Stany Zjednoczone, 32610
- UF Health Cancer Institute - Gainesville
-
Miami, Florida, Stany Zjednoczone, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Plantation, Florida, Stany Zjednoczone, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Tampa, Florida, Stany Zjednoczone, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Stany Zjednoczone, 30342
- Northside Hospital
-
Augusta, Georgia, Stany Zjednoczone, 30912
- Augusta University Medical Center
-
-
Idaho
-
Boise, Idaho, Stany Zjednoczone, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Stany Zjednoczone, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Stany Zjednoczone, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Stany Zjednoczone, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Stany Zjednoczone, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Stany Zjednoczone, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Stany Zjednoczone, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Stany Zjednoczone, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Stany Zjednoczone, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Stany Zjednoczone, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Stany Zjednoczone, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Northwestern University
-
Chicago, Illinois, Stany Zjednoczone, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Stany Zjednoczone, 60612
- University of Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60612
- Rush MD Anderson Cancer Center
-
Maywood, Illinois, Stany Zjednoczone, 60153
- Loyola University Medical Center
-
New Lenox, Illinois, Stany Zjednoczone, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
-
Kansas
-
Chanute, Kansas, Stany Zjednoczone, 66720
- Cancer Center of Kansas - Chanute
-
Dodge City, Kansas, Stany Zjednoczone, 67801
- Cancer Center of Kansas - Dodge City
-
El Dorado, Kansas, Stany Zjednoczone, 67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott, Kansas, Stany Zjednoczone, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Stany Zjednoczone, 67301
- Cancer Center of Kansas-Independence
-
Kansas City, Kansas, Stany Zjednoczone, 66160
- University of Kansas Cancer Center
-
Kingman, Kansas, Stany Zjednoczone, 67068
- Cancer Center of Kansas-Kingman
-
Lawrence, Kansas, Stany Zjednoczone, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Stany Zjednoczone, 67905
- Cancer Center of Kansas-Liberal
-
Manhattan, Kansas, Stany Zjednoczone, 66502
- Cancer Center of Kansas-Manhattan
-
McPherson, Kansas, Stany Zjednoczone, 67460
- Cancer Center of Kansas - McPherson
-
Newton, Kansas, Stany Zjednoczone, 67114
- Cancer Center of Kansas - Newton
-
Parsons, Kansas, Stany Zjednoczone, 67357
- Cancer Center of Kansas - Parsons
-
Pratt, Kansas, Stany Zjednoczone, 67124
- Cancer Center of Kansas - Pratt
-
Salina, Kansas, Stany Zjednoczone, 67401
- Cancer Center of Kansas - Salina
-
Wellington, Kansas, Stany Zjednoczone, 67152
- Cancer Center of Kansas - Wellington
-
Westwood, Kansas, Stany Zjednoczone, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
Wichita, Kansas, Stany Zjednoczone, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, Stany Zjednoczone, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Stany Zjednoczone, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, Stany Zjednoczone, 67208
- Associates In Womens Health
-
Winfield, Kansas, Stany Zjednoczone, 67156
- Cancer Center of Kansas - Winfield
-
-
Kentucky
-
Louisville, Kentucky, Stany Zjednoczone, 40202
- The James Graham Brown Cancer Center at University of Louisville
-
-
Louisiana
-
Baton Rouge, Louisiana, Stany Zjednoczone, 70806
- Baton Rouge General Medical Center
-
Baton Rouge, Louisiana, Stany Zjednoczone, 70809
- Hematology/Oncology Clinic PLLC
-
New Orleans, Louisiana, Stany Zjednoczone, 70112
- Tulane University School of Medicine
-
New Orleans, Louisiana, Stany Zjednoczone, 70121
- Ochsner Medical Center Jefferson
-
Shreveport, Louisiana, Stany Zjednoczone, 71103
- LSU Health Sciences Center at Shreveport
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Fitchburg, Massachusetts, Stany Zjednoczone, 01420
- Simonds-Sinon Regional Cancer Center
-
Worcester, Massachusetts, Stany Zjednoczone, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- University of Michigan Rogel Cancer Center
-
Battle Creek, Michigan, Stany Zjednoczone, 49017
- Bronson Battle Creek
-
Detroit, Michigan, Stany Zjednoczone, 48201
- Wayne State University/Karmanos Cancer Institute
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Stany Zjednoczone, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Stany Zjednoczone, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Stany Zjednoczone, 49009
- Beacon Kalamazoo Cancer Center
-
Kalamazoo, Michigan, Stany Zjednoczone, 49048
- Beacon Kalamazoo
-
Muskegon, Michigan, Stany Zjednoczone, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Stany Zjednoczone, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Stany Zjednoczone, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Stany Zjednoczone, 49677
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Stany Zjednoczone, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Stany Zjednoczone, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, Stany Zjednoczone, 49684
- Munson Medical Center
-
Wyoming, Michigan, Stany Zjednoczone, 49519
- University of Michigan Health - West
-
-
Minnesota
-
Minneapolis, Minnesota, Stany Zjednoczone, 55455
- University of Minnesota/Masonic Cancer Center
-
Rochester, Minnesota, Stany Zjednoczone, 55905
- Mayo Clinic in Rochester
-
-
Missouri
-
Creve Coeur, Missouri, Stany Zjednoczone, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Stany Zjednoczone, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Stany Zjednoczone, 63104
- SSM Health Saint Louis University Hospital
-
-
Montana
-
Anaconda, Montana, Stany Zjednoczone, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Stany Zjednoczone, 59101
- Billings Clinic Cancer Center
-
Billings, Montana, Stany Zjednoczone, 59101
- Saint Vincent Healthcare
-
Billings, Montana, Stany Zjednoczone, 59102
- Saint Vincent Frontier Cancer Center
-
Bozeman, Montana, Stany Zjednoczone, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Stany Zjednoczone, 59405
- Great Falls Clinic
-
Great Falls, Montana, Stany Zjednoczone, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Stany Zjednoczone, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Stany Zjednoczone, 59901
- Logan Health Medical Center
-
Missoula, Montana, Stany Zjednoczone, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Stany Zjednoczone, 59804
- Community Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Stany Zjednoczone, 68123
- Nebraska Medicine-Bellevue
-
Omaha, Nebraska, Stany Zjednoczone, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Stany Zjednoczone, 68118
- Nebraska Medicine-Village Pointe
-
-
New Hampshire
-
Lebanon, New Hampshire, Stany Zjednoczone, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New York
-
Buffalo, New York, Stany Zjednoczone, 14263
- Roswell Park Cancer Institute
-
New York, New York, Stany Zjednoczone, 10065
- NYP/Weill Cornell Medical Center
-
Oswego, New York, Stany Zjednoczone, 13126
- Upstate Cancer Center at Oswego
-
Rochester, New York, Stany Zjednoczone, 14642
- University of Rochester
-
Syracuse, New York, Stany Zjednoczone, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Stany Zjednoczone, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Stany Zjednoczone, 10467
- Children's Hospital at Montefiore
-
The Bronx, New York, Stany Zjednoczone, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Stany Zjednoczone, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Durham, North Carolina, Stany Zjednoczone, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Stany Zjednoczone, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Stany Zjednoczone, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Stany Zjednoczone, 43210
- Ohio State University Comprehensive Cancer Center
-
West Chester, Ohio, Stany Zjednoczone, 45069
- University of Cincinnati Cancer Center-West Chester
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Bend, Oregon, Stany Zjednoczone, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Stany Zjednoczone, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Stany Zjednoczone, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Stany Zjednoczone, 97420
- Bay Area Hospital
-
Newberg, Oregon, Stany Zjednoczone, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Stany Zjednoczone, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City, Oregon, Stany Zjednoczone, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97239
- Oregon Health and Science University
-
Portland, Oregon, Stany Zjednoczone, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Chadds Ford, Pennsylvania, Stany Zjednoczone, 19317
- Christiana Care Health System-Concord Health Center
-
Danville, Pennsylvania, Stany Zjednoczone, 17822
- Geisinger Medical Center
-
Hazleton, Pennsylvania, Stany Zjednoczone, 18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Lewisburg, Pennsylvania, Stany Zjednoczone, 17837
- Geisinger Medical Oncology-Lewisburg
-
Lewistown, Pennsylvania, Stany Zjednoczone, 17044
- Lewistown Hospital
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19111
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15232
- UPMC Hillman Cancer Center
-
Pottsville, Pennsylvania, Stany Zjednoczone, 17901
- Geisinger Cancer Services-Pottsville
-
Scranton, Pennsylvania, Stany Zjednoczone, 18510
- Community Medical Center
-
Selinsgrove, Pennsylvania, Stany Zjednoczone, 17870
- Geisinger Medical Oncology-Selinsgrove
-
State College, Pennsylvania, Stany Zjednoczone, 16801
- Geisinger Medical Group
-
Wilkes-Barre, Pennsylvania, Stany Zjednoczone, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Boiling Springs, South Carolina, Stany Zjednoczone, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- Medical University of South Carolina
-
Clinton, South Carolina, Stany Zjednoczone, 29325
- Prisma Health Cancer Institute - Laurens
-
Easley, South Carolina, Stany Zjednoczone, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Stany Zjednoczone, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Stany Zjednoczone, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Stany Zjednoczone, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Stany Zjednoczone, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Stany Zjednoczone, 29601
- Saint Francis Hospital
-
Greenville, South Carolina, Stany Zjednoczone, 29605
- Prisma Health Greenville Memorial Hospital
-
Greer, South Carolina, Stany Zjednoczone, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Stany Zjednoczone, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57105
- Avera Cancer Institute
-
-
Tennessee
-
Franklin, Tennessee, Stany Zjednoczone, 37067
- Vanderbilt-Ingram Cancer Center Cool Springs
-
Memphis, Tennessee, Stany Zjednoczone, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Stany Zjednoczone, 37204
- Vanderbilt Breast Center at One Hundred Oaks
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
-
Utah
-
American Fork, Utah, Stany Zjednoczone, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, Stany Zjednoczone, 84720
- Sandra L Maxwell Cancer Center
-
Farmington, Utah, Stany Zjednoczone, 84025
- Farmington Health Center
-
Logan, Utah, Stany Zjednoczone, 84321
- Logan Regional Hospital
-
Murray, Utah, Stany Zjednoczone, 84107
- Intermountain Medical Center
-
Ogden, Utah, Stany Zjednoczone, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, Stany Zjednoczone, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, Stany Zjednoczone, 84065
- Riverton Hospital
-
Salt Lake City, Utah, Stany Zjednoczone, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84106
- Utah Cancer Specialists-Salt Lake City
-
Salt Lake City, Utah, Stany Zjednoczone, 84143
- LDS Hospital
-
South Jordan, Utah, Stany Zjednoczone, 84009
- South Jordan Health Center
-
St. George, Utah, Stany Zjednoczone, 84770
- Saint George Regional Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Stany Zjednoczone, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Aberdeen, Washington, Stany Zjednoczone, 98520
- Providence Regional Cancer System-Aberdeen
-
Anacortes, Washington, Stany Zjednoczone, 98221
- Cancer Care Center at Island Hospital
-
Bellingham, Washington, Stany Zjednoczone, 98225
- PeaceHealth Saint Joseph Medical Center
-
Centralia, Washington, Stany Zjednoczone, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Stany Zjednoczone, 98026
- Swedish Cancer Institute-Edmonds
-
Everett, Washington, Stany Zjednoczone, 98201
- Providence Regional Cancer Partnership
-
Issaquah, Washington, Stany Zjednoczone, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Stany Zjednoczone, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Stany Zjednoczone, 98503
- Providence Regional Cancer System-Lacey
-
Longview, Washington, Stany Zjednoczone, 98632
- PeaceHealth Saint John Medical Center
-
Seattle, Washington, Stany Zjednoczone, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Stany Zjednoczone, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Stany Zjednoczone, 98195
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Stany Zjednoczone, 98112
- Kaiser Permanente Washington
-
Seattle, Washington, Stany Zjednoczone, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Stany Zjednoczone, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Seattle, Washington, Stany Zjednoczone, 98109
- Fred Hutchinson Cancer Center
-
Shelton, Washington, Stany Zjednoczone, 98584
- Providence Regional Cancer System-Shelton
-
Spokane, Washington, Stany Zjednoczone, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane, Washington, Stany Zjednoczone, 99218
- MultiCare Deaconess Cancer and Blood Specialty Center - North
-
Spokane Valley, Washington, Stany Zjednoczone, 99216
- MultiCare Deaconess Cancer and Blood Specialty Center - Valley
-
Vancouver, Washington, Stany Zjednoczone, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Stany Zjednoczone, 99362
- Providence Saint Mary Regional Cancer Center
-
Yelm, Washington, Stany Zjednoczone, 98597
- Providence Regional Cancer System-Yelm
-
-
Wisconsin
-
Burlington, Wisconsin, Stany Zjednoczone, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Chippewa Falls, Wisconsin, Stany Zjednoczone, 54729
- Marshfield Clinic-Chippewa Center
-
Eau Claire, Wisconsin, Stany Zjednoczone, 54701
- Marshfield Medical Center-EC Cancer Center
-
Eau Claire, Wisconsin, Stany Zjednoczone, 54701
- Marshfield Clinic Cancer Center at Sacred Heart
-
Fond du Lac, Wisconsin, Stany Zjednoczone, 54937
- Aurora Health Center-Fond du Lac
-
Germantown, Wisconsin, Stany Zjednoczone, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Stany Zjednoczone, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Stany Zjednoczone, 54311
- Aurora BayCare Medical Center
-
Kenosha, Wisconsin, Stany Zjednoczone, 53142
- Aurora Cancer Care-Kenosha South
-
Ladysmith, Wisconsin, Stany Zjednoczone, 54848
- Marshfield Medical Center - Ladysmith
-
Madison, Wisconsin, Stany Zjednoczone, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Stany Zjednoczone, 54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield, Wisconsin, Stany Zjednoczone, 54449
- Marshfield Medical Center-Marshfield
-
Marshfield, Wisconsin, Stany Zjednoczone, 54449
- Marshfield Medical Center
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Stany Zjednoczone, 54548
- Marshfield Medical Center - Minocqua
-
Oshkosh, Wisconsin, Stany Zjednoczone, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Stany Zjednoczone, 53406
- Aurora Cancer Care-Racine
-
Rice Lake, Wisconsin, Stany Zjednoczone, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Stany Zjednoczone, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point, Wisconsin, Stany Zjednoczone, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit, Wisconsin, Stany Zjednoczone, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Stany Zjednoczone, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wausau, Wisconsin, Stany Zjednoczone, 54401
- Marshfield Clinic-Wausau Center
-
Wauwatosa, Wisconsin, Stany Zjednoczone, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Stany Zjednoczone, 53227
- Aurora West Allis Medical Center
-
Weston, Wisconsin, Stany Zjednoczone, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Stany Zjednoczone, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Wyoming
-
Cheyenne, Wyoming, Stany Zjednoczone, 82001
- Cheyenne Regional Medical Center-West
-
Cody, Wyoming, Stany Zjednoczone, 82414
- Billings Clinic-Cody
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
PRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 0)
-
Patients must have paraffin tissue from the diagnostic or relapse biopsy available to be submitted for central pathology review; this review is mandatory prior to registration to confirm eligibility and should be initiated as soon as possible
-
ELIGIBILITY CRITERIA (STEP 1)
-
Diagnosis of World Health Organization (WHO) diffuse large B-cell lymphoma, non-GCB by central review confirmation
-
Patient must be deemed eligible to proceed with high-dose chemotherapy and autologous stem cell transplantation by local transplant center
-
New York Heart Association class I or less; ordinary physical activity does not cause undue fatigue, palpitations, dyspnea, or angina pain; patients 60 years or older must have a left ventricular ejection fraction (LVEF) at rest >= 40% measured by echocardiogram or multi-gated acquisition (MUGA)
-
Diffusion capacity of the lung for carbon monoxide (DLCO) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)
-
Forced expiratory volume in 1 second (FEV1) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)
-
Forced vital capacity (FVC) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)
-
Total bilirubin =< 1.5 x upper limit of normal (ULN) unless isolated hyperbilirubinemia attributed to Gilbert's syndrome
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
-
Creatinine =< 2.0 mg/dL OR creatinine clearance (calculated clearance permitted) >= 40 mL/min by Cockcroft-Gault formula
-
Prothrombin time (PT)/ international normalized ration (INR) < 1.5 x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN
-
Patient must have progressed or be refractory to prior anthracycline-containing chemotherapy (e.g. rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone [R-CHOP], dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab [DA-EPOCH-R], etc)
-
No more than 3 prior regimens for large cell component (e.g. one induction and two salvage therapies); monoclonal antibody alone or involved field/involved site radiotherapy do not count as lines of therapy. Prior CART therapy is allowed and counts as one line of therapy
-
Prior use of ibrutinib is allowed unless patient has had disease progression while receiving ibrutinib
-
Patient must have chemosensitive disease as defined by at least a partial response to salvage therapy at their latest assessment
-
No major surgery =< 7 days prior to registration and no minor surgery =< 3 days prior to registration (with the exception of intravenous access placement, e.g. Hickman or peripherally inserted central catheter [PICC])
-
Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects; therefore, for women of childbearing potential only, a negative serum pregnancy test must be obtained within 14 days prior to registration
- Women of childbearing potential must use adequate contraception from study start to one month after the last dose of protocol therapy; adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence; men must practice complete abstinence or agree to use an adequate contraception method from study start to one month after the last dose of protocol therapy
-
Age >= 18 years
-
Patients should not require chronic use of strong CYP3A inhibitors or strong CYP3A inducers
-
Patients should not require concurrent therapeutic doses of steroids (> 20 mg of prednisone/day or equivalent) unless they need them for the indications; steroids should be discontinued for 14 days before starting protocol treatment
-
Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all other eligibility criteria, and:
- There is no prior history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ T-cell count or B-cell lymphoma
- In the opinion of an expert in HIV disease, prospects for long-term survival are excellent were it not for the diagnosis of lymphoma
- Use of HIV protease inhibitors as part of the anti-HIV regimen OR as a pharmacologic booster is not allowed
- Zidovudine is not allowed
- Once daily combination pills for HIV containing a pharmacologic booster such as cobicistat are not allowed
- Patients with multi-drug resistant HIV are not eligible
-
Patients cannot have:
- Active central nervous system or meningeal involvement by lymphoma; patients with a history of central nervous system (CNS) or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced magnetic resonance imaging (MRI) imaging for at least 91 days prior to registration
- Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy
- A known bleeding diathesis
- Requirement for warfarin or similar vitamin K antagonists; these drugs are prohibited 28 days prior to the first treatment and throughout the trial
- History of stroke or intracranial hemorrhage =< 6 months before treatment
- Currently active, clinically significant hepatic impairment (Child-Pugh class B or C according to the Child Pugh classification
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in study
- Serologic status reflecting active hepatitis B or C infection; patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment; (PCR positive patients will be excluded)
-
Eastern Cooperative Oncology Group (ECOG) performance status must be =< 2
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Potroić
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Arm I (ibrutinib, chemotherapy, autoHCT)
CONDITIONING REGIMEN: Investigators may choose to use either the BEAMi or CBVi regimen. BEAMi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV BID over 1-2 hours and cytarabine IV BID over 1-2 hours on days -5 to -2, and melphalan IV over 20-30 minutes on day -1. CBVi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. TRANSPLANT: In both arms, patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0. CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive ibrutinib PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given IV
Inne nazwy:
Given IV
Inne nazwy:
Given PO
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
Correlative studies
Inne nazwy:
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Inne nazwy:
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Inne nazwy:
Given IV
Inne nazwy:
|
|
Komparator placebo: Arm II (placebo, chemotherapy, autoHCT)
CONDITIONING REGIMEN: Patients receive placebo PO on days -6 to -1 and receive 1 of the 2 conditioning regimens as in Arm I. TRANSPLANT: Patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0. CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive placebo PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover Arm I. |
Correlative studies Given IV
Inne nazwy:
Given IV
Inne nazwy:
Given PO Given IV
Inne nazwy:
Given IV
Inne nazwy:
Correlative studies
Inne nazwy:
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Inne nazwy:
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
Inne nazwy:
Given IV
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
24-month Progression-free Survival (PFS), Defined as the Proportion of Patients Who Are Alive and Progression-free 2 Years From Randomization
Ramy czasowe: Time between registration and disease progression or death, whichever comes first, assessed at 24 months
|
Will be assessed using the Lugano classification. |
Time between registration and disease progression or death, whichever comes first, assessed at 24 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall Survival (OS)
Ramy czasowe: The time between randomization and death from any cause, assessed up to 5 years (60 months)
|
For each arm, the distribution of OS will be estimated using the Kaplan-Meier method. OS will be compared between the two arms using the log-rank test and Cox regression method adjusting for the known predictors. |
The time between randomization and death from any cause, assessed up to 5 years (60 months)
|
|
Time to Hematopoietic Engraftment
Ramy czasowe: First day of one week without platelet transfusion, assessed up to 5 years
|
Will be defined as platelet count greater than or equal to 20,000/uL following nadir. |
First day of one week without platelet transfusion, assessed up to 5 years
|
|
PFS
Ramy czasowe: Time between registration and disease progression or death, whichever comes first, assessed up to 5 years (60 months)
|
For each arm, the distribution of PFS will be estimated using the Kaplan-Meier method. PFS will be compared between the two arms using the log-rank test and Cox regression method adjusting for the known predictors. |
Time between registration and disease progression or death, whichever comes first, assessed up to 5 years (60 months)
|
|
Response Rate Using the Lugano Classification
Ramy czasowe: Up to 60 months
|
The metabolic response proportion following AutoHCT will be compared between the two arms using chi-squared test. |
Up to 60 months
|
|
Treatment-related Mortality
Ramy czasowe: Up to 60 months
|
Treatment-related mortality will be summarized using contingency tables. |
Up to 60 months
|
|
Incidence of Hematologic Toxicity of Ibrutinib Therapy
Ramy czasowe: Up to 60 months
|
Hematologic toxicity will be summarized using contingency tables. |
Up to 60 months
|
|
Incidence of Secondary Malignancies
Ramy czasowe: Up to 60 months
|
Incidence of secondary malignancies will be summarized using contingency tables. |
Up to 60 months
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Fludeoxyglucose Positron Emission Tomography (FDG-PET) Imaging Results
Ramy czasowe: Baseline
|
PFS and OS will be compared between PET/computed tomography (CT) positive and negative groups using the two-sample log-rank test with a 2-sided alpha of 5%. A Cox regression model will be conducted to regress PFS and OS on PET/CT positivity. Deauville criteria analyses will be conducted with cutoffs at scores of 2 and 3, and quantitative measurements, e.g. delta standard uptake value (SUV), %SUV decline and %MTV decline, in place of the dichotomous FDG-PET/CT outcome. Positive/negative predictive values, sensitivity and specificity of PET/CT further estimated by dichotomizing the PFS and OS at 2 years. |
Baseline
|
|
GSTT1 Null Allele Expression
Ramy czasowe: Baseline
|
GSTT1 null allele expression will be associated with carmustine toxicity. Quantified using the standard Common Terminology Criteria for Adverse Events and changes in diffusing capacity of the lungs for carbon monoxide from baseline. |
Baseline
|
|
Single-nuclear Polymorphisms (SNPs) in the BCNU Metabolism or Damage Repair Pathways
Ramy czasowe: Baseline
|
All SNPs will be evaluated for deviation from Hardy-Weinberg. In the absence of a hypothesized effect, analyses will be powered for allele dosing (i.e., additive) effects. The Cochran-Armitage test (for binary endpoints), Jonkheere-Terpstra test (for quantitative traits including biomarker or gene expressions in serum or tumor ribonucleic acid) and the Cox score test (for censored time-to-event outcomes) will be used to quantify marginal associations. Multivariable models, with molecular, clinical and demographic variables, will be constructed using conditional inference trees and random forests. |
Baseline
|
|
BCR Pathway Mutations
Ramy czasowe: Baseline
|
The mutation of CD79a/b, caspase recruitment domain family, member 11 (CARD11), tumor necrosis factor, alpha-induced protein 3 TNFAIP3), and myeloid differentiation primary response 88 (MYD88) will be associated with each outcome in the ibrutinib arm (Arm A) using the chi-squared test for response rate and the log-rank test for each censored outcome. Similar analyses will be conducted for the placebo arm (Arm B) to show that the association between mutation and the outcomes observed in the ibrutinib arm is not observed in the placebo arm. |
Baseline
|
|
BCL2, MYC, and Ki67 Expression in Tissue Samples by Immunohistochemistry (IHC)
Ramy czasowe: Baseline
|
The expression of BCL2, MYC, and Ki67 will be analyzed to assess whether they affect clinical outcomes. |
Baseline
|
|
MYC Translocations
Ramy czasowe: Baseline
|
Translocations in MYC with or without BCL2, and BCL6 will be analyzed to determine whether they are related to poor outcomes and whether ibrutinib modifies the prognosis. |
Baseline
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Charalambos B Andreadis, Alliance for Clinical Trials in Oncology
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Szacowany)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Aminokwasy, peptydy i białka
- Organiczne chemikalia
- Związki heterocykliczne, 1-ring
- Związki heterocykliczne
- Techniki śledcze
- Lecznictwo
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Procedury chirurgiczne, operacyjny
- Kwasy nukleinowe, nukleotydy i nukleozydy
- Węglowodory
- Węglowodory, cykliczne
- Węglowodany
- Podofilotoksyna
- Tetrahydronafthalenes
- Naftaleny
- Policykliczne aromatyczne węglowodory
- Węglowodory, aromatyczne
- Związki policykliczne
- Glukozydy
- Glikozydy
- Przeszczep
- Amides
- Aminokwasy
- Cytydyna
- Nukleozydy pirymidynowe
- Pirymidyn
- Usługi zdrowotne
- Zakłady opieki zdrowotnej i usługi
- Pobieżne usługi zdrowotne
- Mostki fosforamidu
- Związki musztardy azotu
- Związki musztardy
- Węglowodory, uboczne
- Fosforamidy
- Związki okorosfosforowe
- Nukleozydy
- Arabinonukleozydy
- Przeszczep komórki
- Terapia oparta na komórkach i tkankach
- Terapia biologiczna
- Fenyloalanina
- Aminokwasy, aromatyczne
- Aminokwasy, cykliczne
- Testy genetyczne
- Techniki genetyczne
- Usługi genetyczne
- Usługi diagnostyczne
- Związki nitrosourea
- Mocznik
- Związki nitroso
- Przeszczep tkanki
- Cyklofosfamid
- Cytarabina
- Karmustyna
- Melfalan
- Etopozyd
- Przeszczep komórek macierzystych
- Ibrutinib
- Testy farmakogenomiczne
- Przeszczep szpiku kostnego
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- NCI-2015-00668
- U10CA180821 (Grant/umowa NIH USA)
- NCI-2015-00668 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- BMT CTN 1201
- A051301 (Inny identyfikator: CTEP)
- A051301
- A051301 (Inny identyfikator: Alliance for Clinical Trials in Oncology)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .